UNSPSC 51291806: Nitrafudam hydrochloride

This classification denotes an antidepressant agent with the molecular formula C11H9N3O3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 555ERF3D9O. The term nitrafudam hydrochloride is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule nitrafudam hydrochloride under HS 29321900 and SITC 51569. As of Q4 2014, NITRAFUDAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nitrafudam hydrochloride bears US NLM identifiers UMLS ID C2347355 and NCI Concept Code C73807.

SMILES: C1CCC(C(C1)C2CCC(O2)C(=N)N)[N+](=O)[O-].CL.

UNSPSC 51291806 Nitrafudam hydrochloride is a Commodity code that nominally designates a single pharmaceutical product, but recent state and local solicitations tagged with this code show minimal direct activity for nitrafudam hydrochloride itself. Instead, the opportunities reflect broader pharmaceutical procurement — naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs. State and local issuing bodies pursuing pharmaceutical supply through this taxonomy tier include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving participating state and local government facilities). The work involves establishing supply contracts for medications and medical countermeasures, with vendor qualification requirements typically including FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and specified insurance coverage.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023 (note: date discrepancy in source). Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor information on direct-to-manufacturer prescription programs for self-insured employee health plans, with a response deadline of April 3, 2026. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative purchasing vehicle, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract awards effective July 1, 2026. Vendors must work through authorized wholesalers and meet strict compliance and pricing documentation standards, with contract terms typically two years plus optional renewals.